Breaking Down Hangzhou Alltest Biotech Co., Ltd. Financial Health: Key Insights for Investors

Curious whether Hangzhou Alltest Biotech Co., Ltd. (688606.SS) is a growth story or a value trap? In the quarter ending September 30, 2025 the company posted revenue of 203.23 million CNY (down 8.26% sequentially) while trailing twelve‑month revenue stood at 881.63 million CNY (up 8.47% YoY), supporting a 2024 full‑year top line of 866.58 million CNY (up 14.83% vs. 2023); profitability metrics show TTM net income of 294.76 million CNY with TTM operating income of 280.1 million CNY and an operating margin of 31.53%, basic EPS of 3.83 CNY in 2024 (a 67.98% increase YoY) and ROE at 7.84% (up 3.32 percentage points), while valuation sits at a market cap of 5.43 billion CNY (P/E 17.73, P/S 5.59) and an enterprise value of 2.97 billion CNY against a reportedly debt‑free balance sheet-juxtapose these hard numbers with cash‑flow outflows of -50.4 million CNY in "other activities," concentration and regulatory risks in the POCT and IVD markets, and clear growth levers like a new factory (200 million units annual capacity), monthly POCT launches, and international trade show exposure to decide whether the multiple reflects justified growth expectations or elevated risk; read on for a line‑by‑line financial breakdown, risk scorecard, and valuation sensitivity analysis.

Hangzhou Alltest Biotech Co., Ltd. (688606.SS) - Revenue Analysis

• Q3 2025 revenue: 203.23 million CNY (-8.26% vs prior quarter)
• TTM revenue (as of 2025-09-30): 881.63 million CNY (+8.47% YoY)
• FY2024 revenue: 866.58 million CNY (+14.83% YoY)
• Revenue per employee: ~909,840 CNY (969 employees)
• Market capitalization: 4.93 billion CNY; P/S ratio: 5.59
• Revenue per share (FY2024): 10.94 CNY

• Quarter-to-quarter softness (Q3 2025) contrasts with solid trailing and annual growth, indicating potential seasonality or mix shifts.
• Revenue per employee (~909.8k CNY) suggests operational productivity benchmarks for peer comparisons.
• P/S of 5.59 positions valuation relative to sales - consider alongside profit margins and growth trajectory.

Hangzhou Alltest Biotech Co., Ltd. (688606.SS) - Profitability Metrics

Hangzhou Alltest Biotech's profitability profile through mid-2025 shows strong operational margins and notable EPS growth year-over-year. Key top-line and bottom-line indicators point to healthy earnings generation and improving returns to shareholders.

• Quarter (ending 2025-06-30) net income: 70.80 million CNY; EPS: 0.89 CNY.
• TTM (as of 2025-06-30) net income: 294.76 million CNY; TTM EPS: 3.72 CNY.
• TTM operating income: 280.10 million CNY; operating margin: 31.53%.
• FY2024 ROE: 7.84% (up 3.32 percentage points vs prior year).
• FY2024 basic EPS: 3.83 CNY (increase of 67.98% YoY).
• Profit before non-recurring items: 23.94 million CNY (up 62.92% YoY).

Investors evaluating operational efficiency and earnings quality should weigh the solid operating margin (31.53% TTM) alongside EPS momentum and the uplift in ROE. For strategic context and company positioning, see Mission Statement, Vision, & Core Values (2026) of Hangzhou Alltest Biotech Co., Ltd.

Hangzhou Alltest Biotech Co., Ltd. (688606.SS) - Debt vs. Equity Structure

• Market capitalization: 5.43 billion CNY
• Enterprise value: 2.97 billion CNY
• Reported outstanding debt: None (debt-free)
• Price-to-earnings (P/E) ratio: 17.73
• Weighted average return on equity (ROE): 7.84% (up 3.32 percentage points year-over-year)
• Total assets at period-end: 418.65 million CNY (+1.71% vs. period start)

Hangzhou Alltest Biotech Co., Ltd. (688606.SS) Liquidity and Solvency

Key liquidity and solvency signals for the three months ended March 31, 2025, reflect limited operating cash detail and several explicit zero or negative items disclosed for the period.

• Cash flow from operations: not specified in the available data (company did not disclose a numeric amount for the period).
• Cash flow from deferred tax: 0.0 million CNY - no material tax-related cash movements recorded.
• Net cash from discontinued operating activities: 0.0 million CNY - no discontinued operations contributing cash flows.
• Asset impairment charge: 0.0 million CNY - no impairments recognized in the period.
• Stock-based compensation: 0.0 million CNY - no share-based pay-related cash impact.
• Cash flow from other activities: -50.4 million CNY - a material net cash outflow from other activities in the quarter.

Practical implications for investors:

• The lack of a disclosed operating cash flow number reduces transparency and makes short-term liquidity assessment dependent on balance sheet cash balances and subsequent disclosures.
• A -50.4 million CNY outflow from other activities in a single quarter can materially affect short-term free cash flow and liquidity if not offset by operating inflows or financing receipts.
• Zero amounts in deferred tax, discontinued operations, impairments, and stock-based compensation simplify the quarter's cash movement drivers but do not substitute for an explicit operating cash flow figure.

For broader context on the company's background and business model, see Hangzhou Alltest Biotech Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Hangzhou Alltest Biotech Co., Ltd. (688606.SS) - Valuation Analysis

• Market Capitalization: 5.43 billion CNY
• P/E Ratio (TTM): 17.73 - moderate valuation relative to earnings
• P/S Ratio: 5.59 - above industry average, signals higher growth expectations
• Enterprise Value (EV): 2.97 billion CNY - reflects net of debt/cash
• Revenue per Share (FY 2024): 10.94 CNY
• Basic EPS (FY 2024): 3.83 CNY - +67.98% YoY
• Profit margin before non-recurring items: 23.94 million CNY - +62.92% YoY

• A P/E of 17.73 with EPS growth near 68% suggests current earnings justify part of the share price, but durability of growth is critical.
• A P/S of 5.59 indicates the market expects continued revenue expansion; compare to peers to gauge premium sustainability.
• EV at 2.97 billion CNY vs. market cap of 5.43 billion CNY hints at net cash or low net debt-clarify from the balance sheet for leverage assessment.
• Strong improvement in profit before non-recurring items (+62.92%) supports margin expansion narratives and earnings quality.

Hangzhou Alltest Biotech Co., Ltd. (688606.SS) - Risk Factors

• The company operates in a highly competitive in vitro diagnostic (IVD) reagent market, where pricing pressure and market share shifts are common. Competitor price cuts of 5-15% in core product lines can compress revenue growth and force margin concessions.
• Fluctuations in raw material costs (e.g., antibodies, reagents, plastics) can materially affect gross margins. A sustained 10% rise in key input costs could reduce gross margin by multiple percentage points depending on product mix and pass-through ability.
• Regulatory changes in China and export markets may delay product approvals or increase compliance costs, affecting time-to-market and incremental R&D/QA spending.
• Dependence on a limited number of large customers or hospital group contracts concentrates receivable and revenue risk; loss or renegotiation of one or two major accounts could reduce annual revenues by a high-single-digit to double-digit percentage depending on concentration.
• International expansion exposes the company to geopolitical tensions, tariffs, and currency fluctuations - FX swings of ±5-10% can affect translated revenue and reported margins from overseas sales.
• Rapid technological advancements by competitors (e.g., point-of-care molecular tests, next-gen immunoassays) risk product obsolescence and require ongoing capital allocation to R&D to maintain competitiveness.

• Financial covenant and liquidity risk: stress-testing liquidity under scenarios such as a 20% revenue decline or 50% elongation of receivables (days sales outstanding). Investors should review the company's latest cash, short-term investments, and debt maturities to assess runway.
• Operational ramp risk: scaling manufacturing for international demand can require capital expenditure and working capital increases; a rapid ramp could raise capex by tens of millions RMB in a single year depending on factory expansion plans.
• Concentration of suppliers and single-source components create supply-chain vulnerability - plan for alternative suppliers and buffer inventories where cost-effective.

Hangzhou Alltest Biotech Co., Ltd. (688606.SS) - Growth Opportunities

• POCT focus and product cadence: the company reports launching new POCT products monthly, accelerating SKU growth and channel fill rates.
• Global trade-show exposure: active participation at ADLM 2025 and MEDICA 2025 increases visibility with distributors, hospitals, and OEM partners in North America, Europe, Middle East and Asia-Pacific.
• Capacity expansion: a newly established factory with an annual production capacity of 200 million diagnostic reagents and electronic instruments supports scale-up and commercialization plans.
• Operational efficiency: investments in internal management improvements and production automation aim to compress manufacturing lead times, reduce per-unit cost and improve quality consistency.
• Market diversification: development of veterinary diagnostics and gastrointestinal-health-focused products opens distinct revenue streams and reduces reliance on single-use human POCT products.
• Repeated international engagement: continued show presence (ADLM 2025, MEDICA 2025) reinforces global partnership pipelines and licensing opportunities.

• Scenario analysis - illustrative revenue potential from new factory (annual):
• Conservative: 40% utilization × 200M units × $1.5/unit ≈ $120M revenue
• Base: 60% utilization × 200M × $2.5/unit ≈ $300M revenue
• Aggressive: 85% utilization × 200M × $3.5/unit ≈ $595M revenue

• Utilization rate of new factory - each 10% incremental utilization of 200M capacity equates to 20M units of output; at $2.5/unit that's ~$50M incremental revenue per 10% utilization.
• Product-mix uplift - moving from low ASP (average selling price) strips toward instrument-linked assays can raise blended ASP materially (illustrative: $1.5 → $3.5, >2x revenue per unit).
• Export penetration - successful distributor deals from trade-show engagements can increase ARPU (average revenue per unit) and shorten receivable cycles if denominated in stronger FX markets.
• Cost and margin impact from automation - anticipated reductions in COGS of 5-15% with improved automation and scale, driving operating margin expansion.

• R&D intensity: sustaining monthly launches requires continuous R&D investment - monitor R&D spend as % of revenue to gauge innovation runway versus margin pressure.
• Regulatory and reimbursement timelines: international market access (EU/US) depends on certifications (CE/IVDR, FDA) that affect time-to-revenue for exported SKUs.
• Working capital and capex: factory ramp and automation require capital - track capital expenditures and incremental working capital tied to inventory build-up ahead of commercialization.
• Product segmentation traction: adoption rates in veterinary and gastrointestinal diagnostics will determine diversification benefits and potential cross-sell into existing distributor networks.